Optibiotix revenues soar in second half

Optibiotix turned in revenues of £541,000 in the year ended 30 November, a 183% year-on-year increase - 85% of which was recognised in the second half.

The AIM-listed firm, which makes the Lactobacillus plantarum cardiovascular probiotic and SlimBiome functional ingredient, anticipates further revenue growth in 2019 as existing deals contribute to full-year revenues, and partners continue to grow sales.

Chief executive Stephen O'Hara said: "The last 12 months has seen Optibiotix transition from a research and development company to a commercial business with significant deal flow and rapidly growing revenues."

"As these revenues grow and we continue to build trading histories with an increasing number of partners, we will be in a position to provide reliable forecasts to the market."

Optibiotix intends to report its final results for the year ended 30 November 2018 by 30 April 2019.

As of 0845 GMT, Optibiotix shares had slumped 5.89% to 86.11p.